Unnamed: 0,title,date,stock,sentiment
934018.0,"Benzinga's Top Upgrades, Downgrades For June 8, 2020",2020-06-08 09:44:00-04:00,NVRO,positive
934019.0,10 Biggest Price Target Changes For Monday,2020-06-08 08:35:00-04:00,NVRO,neutral
934020.0,"UBS Upgrades Nevro to Neutral, Raises Price Target to $132",2020-06-08 07:44:00-04:00,NVRO,neutral
934021.0,Nevro Appoints Finance Executive Roderick MacLeod As Chief Financial Officer,2020-06-04 07:14:00-04:00,NVRO,neutral
934022.0,Nevro Reports CE Mark Approval Of Senza Omnia Spinal Cord Stimulation System To Treat Chronic Pain,2020-05-14 07:17:00-04:00,NVRO,positive
934023.0,"SunTrust Robinson Humphrey Maintains Buy on Nevro, Raises Price Target of $135",2020-05-06 12:09:00-04:00,NVRO,neutral
934024.0,"JP Morgan Maintains Neutral on Nevro, Raises Price Target to $100",2020-05-06 10:19:00-04:00,NVRO,positive
934025.0,"Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $135",2020-05-06 09:02:00-04:00,NVRO,negative
934026.0,"Nevro Q1 EPS $(0.780) Beats $(0.970) Estimate, Sales $87.467M Miss $89.460M Estimate",2020-05-05 16:40:00-04:00,NVRO,negative
934027.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,NVRO,positive
934028.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,NVRO,neutral
934029.0,"Nevro Reports Federal Circuit Rules In Its Favor, Upholds Validity Of Co.'s Patent Claims In Litigation Against Boston Scientific",2020-04-09 12:44:00-04:00,NVRO,positive
934030.0,"Morgan Stanley Maintains Overweight on Nevro, Lowers Price Target to $113",2020-04-03 09:54:00-04:00,NVRO,negative
934031.0,"JP Morgan Maintains Neutral on Nevro, Lowers Price Target to $90",2020-04-02 12:13:00-04:00,NVRO,positive
934032.0,"Canaccord Genuity Maintains Buy on Nevro, Lowers Price Target to $114",2020-04-02 11:59:00-04:00,NVRO,negative
934033.0,"SunTrust Robinson Humphrey Maintains Buy on Nevro, Lowers Price Target to $120",2020-04-02 11:16:00-04:00,NVRO,negative
934034.0,"Wells Fargo Maintains Overweight on Nevro, Lowers Price Target to $126",2020-04-02 09:09:00-04:00,NVRO,negative
934035.0,"Nevro shares are trading lower after the company announced a common stock offering of 1.6 million shares at $84 per share. UPDATE: Shares have since reversed, now higher.",2020-04-02 08:51:00-04:00,NVRO,positive
934036.0,Nevro Corp Announces Pricing Concurrent Offering Of 1.6M Shares Of Its Common Stock At A Public Offering Price Of $84/Share,2020-04-02 08:12:00-04:00,NVRO,positive
934037.0,"The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation",2020-04-02 07:57:00-04:00,NVRO,positive
934038.0,Nevro Announces 1.625M Common Stock Offering,2020-04-01 16:42:00-04:00,NVRO,neutral
934039.0,Nevro Sees Prelim. Q1 Sales $86.4M-$86.9M vs $96.96M Est.; Says As Of Dec. 31 Had $238M In Cash And Equivalents,2020-04-01 16:09:00-04:00,NVRO,neutral
934040.0,"Morgan Stanley Maintains Overweight on Nevro, Lowers Price Target to $118",2020-03-27 09:53:00-04:00,NVRO,negative
934041.0,"Citigroup Maintains Buy on Nevro, Lowers Price Target to $130",2020-03-27 09:01:00-04:00,NVRO,negative
934042.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,NVRO,negative
934043.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,NVRO,positive
934044.0,75 Stocks Moving In Wednesday's Mid-Day Session,2020-02-26 12:18:00-05:00,NVRO,neutral
934045.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-26 10:17:00-05:00,NVRO,neutral
934046.0,"Benzinga's Top Upgrades, Downgrades For February 26, 2020",2020-02-26 10:02:00-05:00,NVRO,positive
934047.0,"Wells Fargo Maintains Overweight on Nevro, Raises Price Target to $158",2020-02-26 09:28:00-05:00,NVRO,negative
934048.0,"JP Morgan Maintains Neutral on Nevro, Raises Price Target to $130",2020-02-26 07:54:00-05:00,NVRO,positive
934049.0,"Canaccord Genuity Upgrades Nevro to Buy, Raises Price Target to $153",2020-02-26 05:33:00-05:00,NVRO,neutral
934050.0,Nevro Reaffirms FY20 Sales Guidance Of $435M-$440M vs $437.06M Est.,2020-02-25 16:12:00-05:00,NVRO,neutral
934051.0,"Nevro Q4 EPS $(0.44) Beats $(0.62) Estimate, Sales $114.4M Beat $111.8M Estimate",2020-02-25 16:11:00-05:00,NVRO,neutral
934052.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,NVRO,negative
934053.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,NVRO,neutral
934054.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,NVRO,negative
934055.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,NVRO,neutral
934056.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,NVRO,negative
934057.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,NVRO,negative
934058.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,NVRO,positive
934059.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,NVRO,positive
934060.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-29 10:16:00-05:00,NVRO,neutral
934061.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,NVRO,neutral
934062.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,NVRO,positive
934063.0,27 Medical Devices Stocks Moving In Monday's Session,2020-01-27 12:48:00-05:00,NVRO,neutral
934064.0,Stocks That Hit 52-Week Highs On Monday,2020-01-27 10:33:00-05:00,NVRO,neutral
934065.0,"Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $142",2020-01-27 10:28:00-05:00,NVRO,negative
934066.0,10 Biggest Price Target Changes For Monday,2020-01-27 08:56:00-05:00,NVRO,neutral
934067.0,"JMP Securities Maintains Market Outperform on Nevro, Raises Price Target to $150",2020-01-27 07:42:00-05:00,NVRO,positive
934068.0,"The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study",2020-01-24 07:43:00-05:00,NVRO,negative
934069.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,NVRO,positive
934070.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-22 10:17:00-05:00,NVRO,neutral
934071.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,NVRO,negative
934072.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,NVRO,neutral
934073.0,"UBS Maintains Sell on Nevro, Raises Price Target to $84",2020-01-15 08:59:00-05:00,NVRO,neutral
934074.0,"Nevro Sees Prelim. Q4 Sales $114.4M vs $109.73M Est., Prelim. FY19 Sales $390.3M vs $385.65M Est.; Sees FY20 Sales $435M-$440M vs $433.08M Est.",2020-01-14 07:04:00-05:00,NVRO,neutral
934075.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,NVRO,positive
934076.0,"Benzinga's Top Upgrades, Downgrades For January 8, 2020",2020-01-08 10:56:00-05:00,NVRO,positive
934077.0,"SunTrust Robinson Humphrey Initiates Coverage On Nevro with Buy Rating, Announces $132 Price Target",2020-01-08 09:51:00-05:00,NVRO,neutral
934078.0,"The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering",2020-01-07 07:57:00-05:00,NVRO,negative
934079.0,Oppenheimer Downgrades Nevro to Perform,2020-01-06 07:11:00-05:00,NVRO,neutral
934080.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,NVRO,negative
934081.0,"The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe",2020-01-02 08:46:00-05:00,NVRO,negative
934082.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,NVRO,negative
934083.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,NVRO,negative
934084.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,NVRO,neutral
934085.0,"JP Morgan Maintains Neutral on Nevro, Raises Price Target to $96",2019-12-20 09:40:00-05:00,NVRO,positive
934086.0,"Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $125",2019-12-17 09:16:00-05:00,NVRO,negative
934087.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,NVRO,positive
934088.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,NVRO,neutral
934089.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,NVRO,positive
934090.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,NVRO,neutral
934091.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,NVRO,positive
934092.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,NVRO,neutral
934093.0,"UBS Maintains Sell on Nevro, Raises Price Target to $77",2019-11-08 07:43:00-05:00,NVRO,neutral
934094.0,94 Biggest Movers From Yesterday,2019-11-08 06:01:00-05:00,NVRO,neutral
934095.0,75 Stocks Moving In Thursday's Mid-Day Session,2019-11-07 12:19:00-05:00,NVRO,neutral
934096.0,"Canaccord Genuity Maintains Hold on Nevro, Raises Price Target to $88",2019-11-07 11:13:00-05:00,NVRO,neutral
934097.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-07 10:16:00-05:00,NVRO,neutral
934098.0,"Benzinga's Top Upgrades, Downgrades For November 7, 2019",2019-11-07 09:32:00-05:00,NVRO,positive
934099.0,"Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $100",2019-11-07 09:26:00-05:00,NVRO,negative
934100.0,"JP Morgan Maintains Neutral on Nevro, Raises Price Target to $80",2019-11-07 08:04:00-05:00,NVRO,positive
934101.0,"Wells Fargo Maintains Outperform on Nevro, Raises Price Target to $105",2019-11-07 07:51:00-05:00,NVRO,positive
934102.0,"Oppenheimer Upgrades Nevro to Outperform, Announces $106 Price Target",2019-11-07 06:52:00-05:00,NVRO,neutral
934103.0,Nevro Raises FY19 Sales Guidance From $368M-$374M To $484M-$386M vs $373.19M Est.,2019-11-06 16:50:00-05:00,NVRO,neutral
934104.0,"Nevro Q3 EPS $(0.58) Beats $(0.86) Estimate, Sales $100.2M Beat $92.8M Estimate",2019-11-06 16:48:00-05:00,NVRO,neutral
934105.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,NVRO,positive
934106.0,Nevro Recieves FDA Approval For Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain,2019-11-05 07:28:00-05:00,NVRO,positive
934107.0,Nevro Announces US Launch Of Senza Omnia Spinal Cord Stimulation System To Treat Chronic Pain,2019-11-05 07:20:00-05:00,NVRO,negative
934108.0,Oppenheimer Initiates Coverage On Nevro with Perform Rating,2019-10-22 07:12:00-04:00,NVRO,neutral
934109.0,"Wells Fargo Maintains Outperform on Nevro, Raises Price Target to $86",2019-10-09 09:27:00-04:00,NVRO,positive
934110.0,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans",2019-09-13 07:40:00-04:00,NVRO,neutral
934111.0,"The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study",2019-09-12 07:38:00-04:00,NVRO,negative
934112.0,Nevro Announces Completion Of Patient Enrollment In  Multicenter Randomized Controlled Trial Of High Frequency Spinal Cord Stimulation For Painful Diabetic Neuropathy,2019-08-28 07:08:00-04:00,NVRO,negative
934113.0,"Hearing Pacific Square Made Cautious Comments On Nevro, Unconfirmed",2019-08-26 10:04:00-04:00,NVRO,negative
934114.0,Stocks That Hit 52-Week Highs On Thursday,2019-08-22 10:32:00-04:00,NVRO,neutral
934115.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,NVRO,positive
934116.0,Stocks That Hit 52-Week Highs On Wednesday,2019-08-21 10:17:00-04:00,NVRO,neutral
934117.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,NVRO,negative
934118.0,10 Biggest Price Target Changes For Monday,2019-08-12 09:12:00-04:00,NVRO,neutral
934119.0,"JMP Securities Reiterates Market Outperform on Nevro, Raises Price Target to $90",2019-08-12 07:39:00-04:00,NVRO,positive
934120.0,90 Biggest Movers From Friday,2019-08-12 05:49:00-04:00,NVRO,neutral
934121.0,75 Stocks Moving In Friday's Mid-Day Session,2019-08-09 14:06:00-04:00,NVRO,neutral
934122.0,A List Of Stocks Reaching New 52-Week Highs,2019-08-09 10:29:00-04:00,NVRO,positive
934123.0,Nevro Shares Spike 17% Higher at the Open; Co Reported Narrower than Expected Loss on Thursday,2019-08-09 09:38:00-04:00,NVRO,neutral
934124.0,"Canaccord Genuity Maintains Hold on Nevro, Raises Price Target to $59",2019-08-09 07:45:00-04:00,NVRO,neutral
934125.0,Nevro Guides FY19 Revenues Of $368M-$374M Vs. $366.97M Estimate,2019-08-08 16:58:00-04:00,NVRO,neutral
934126.0,"Nevro Q2 EPS $(0.91) Beats $(0.97) Estimate, Sales $93.571M Beat $88.4M Estimate",2019-08-08 16:57:00-04:00,NVRO,neutral
934127.0,"Nevro Announces Court Order Granting Preliminary Injunction Against Stimwave Technologies, Inc.",2019-07-25 07:51:00-04:00,NVRO,positive
934128.0,"Nevro Names Pres, CEO Keith Grossman Chair",2019-05-20 17:00:00-04:00,NVRO,neutral
934129.0,72 Biggest Movers From Friday,2019-05-13 05:09:00-04:00,NVRO,neutral
934130.0,62 Stocks Moving In Friday's Mid-Day Session,2019-05-10 12:35:00-04:00,NVRO,neutral
934131.0,Nevro shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results. The company also issued Q2 sales guidance below analyst estimates. Canaccord Genuity downgraded the stock from Buy to Hold.,2019-05-10 10:25:00-04:00,NVRO,neutral
934132.0,10 Biggest Price Target Changes For Friday,2019-05-10 09:41:00-04:00,NVRO,neutral
934133.0,"Benzinga's Top Upgrades, Downgrades For May 10, 2019",2019-05-10 09:24:00-04:00,NVRO,positive
934134.0,25 Stocks Moving In Friday's Pre-Market Session,2019-05-10 08:35:00-04:00,NVRO,neutral
934135.0,"Morgan Stanley Maintains Overweight on Nevro Corp. Common Stock, Lowers Price Target to $64",2019-05-10 08:04:00-04:00,NVRO,negative
934136.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,NVRO,negative
934137.0,"Canaccord Genuity Downgrades Nevro Corp. Common Stock to Hold, Lowers Price Target to $50",2019-05-10 07:21:00-04:00,NVRO,negative
934138.0,"JMP Securities Maintains Market Outperform on Nevro Corp. Common Stock, Lowers Price Target to $70",2019-05-10 07:21:00-04:00,NVRO,positive
934139.0,Nevro shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results; the company also issued Q2 sales guidance below analyst estimates.,2019-05-09 17:32:00-04:00,NVRO,neutral
934140.0,Nevro Sees Q2 Sales $87M-$89M vs $99.49M,2019-05-09 17:16:00-04:00,NVRO,neutral
934141.0,"Nevro Corp. Q1 EPS $(1.45) Misses $(0.67) Estimate, Sales $82.15M Miss $87.49M Estimate",2019-05-09 17:15:00-04:00,NVRO,negative
934142.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,NVRO,neutral
934143.0,Shares of several medical device companies are trading lower with the healthcare sector. Healthcare has seen weakness recently due to concerns over the future of the Affordable Act under Trump and healthcare policy uncertainty ahead of the 2020 election.,2019-04-17 12:45:00-04:00,NVRO,negative
934144.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Mar. 21, 2019",2019-03-21 11:26:00-04:00,NVRO,positive
934145.0,5 Biggest Price Target Changes For Thursday,2019-03-21 10:00:00-04:00,NVRO,neutral
934146.0,"Benzinga's Top Upgrades, Downgrades For March 21, 2019",2019-03-21 09:19:00-04:00,NVRO,positive
934147.0,"Morgan Stanley Upgrades Nevro to Overweight, Raises Price Target to $70",2019-03-21 07:43:00-04:00,NVRO,negative
934148.0,52 Biggest Movers From Yesterday,2019-03-21 04:59:00-04:00,NVRO,neutral
934149.0,Mid-Afternoon Market Update: Fed Expects No Interest Rate Hikes In 2019; Dow Down Over 100 Points,2019-03-20 15:36:00-04:00,NVRO,positive
934150.0,"Nevro's C-Suite, Board Changes Should 'Mark The Turnaround Of The Organization,' BMO Says In Upgrade",2019-03-20 12:41:00-04:00,NVRO,neutral
934151.0,"UPDATE: Bank Of America Upgrades Nevro, Raises Target From $50 To $70 As Firm Views New CEO Keith Grossman As 'arguably the best SMid cap commercial turn-around CEO in MedTech'",2019-03-20 12:20:00-04:00,NVRO,positive
934152.0,41 Stocks Moving In Wednesday's Mid-Day Session,2019-03-20 12:00:00-04:00,NVRO,neutral
934153.0,Mid-Day Market Update: Westport Fuel Systems Falls Following Downbeat Q4 Results; Nevro Shares Surge,2019-03-20 12:00:00-04:00,NVRO,positive
934154.0,Mid-Morning Market Update: Markets Open Lower; General Mills Earnings Top Estimates,2019-03-20 10:12:00-04:00,NVRO,negative
934155.0,10 Biggest Price Target Changes For Wednesday,2019-03-20 09:41:00-04:00,NVRO,neutral
934156.0,Wells Fargo Upgrades Nevro to Outperform,2019-03-20 09:35:00-04:00,NVRO,positive
934157.0,"Benzinga's Top Upgrades, Downgrades For March 20, 2019",2019-03-20 09:12:00-04:00,NVRO,positive
934158.0,Nevro shares are trading higher after the company announced it reached a management agreement with hedge fund Broadfin Capital and two banks upgraded their recommendations of the stock.,2019-03-20 08:50:00-04:00,NVRO,positive
934159.0,"The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company",2019-03-20 07:46:00-04:00,NVRO,negative
934160.0,30 Stocks Moving In Wednesday's Pre-Market Session,2019-03-20 07:38:00-04:00,NVRO,neutral
934161.0,"BMO Capital Upgrades Nevro to Outperform, Raises Price Target to $67",2019-03-20 07:02:00-04:00,NVRO,neutral
934162.0,"Bank of America Upgrades Nevro to Buy, Raises Price Target to $70",2019-03-20 06:56:00-04:00,NVRO,neutral
934163.0,Nevro Names D. Keith Grossman President And CEO,2019-03-19 16:37:00-04:00,NVRO,neutral
934164.0,Nevro Option Alert: Apr 18 $50 Calls at the Ask: 770 @ $1.351 vs 33 OI; Earnings 5/6 After Close [est] Ref=$44.43,2019-03-11 12:18:00-04:00,NVRO,positive
934165.0,71 Biggest Movers From Friday,2019-02-25 05:04:00-05:00,NVRO,neutral
934166.0,Nevro Sees FY19 Sales $400M-$410M vs $419.3M Estimate,2019-02-21 16:21:00-05:00,NVRO,neutral
934167.0,"Nevro Corp. Common Stock Q4 EPS $(0.32) Misses $(0.21) Estimate, Sales $107.944M Beat $107.1M Estimate",2019-02-21 16:20:00-05:00,NVRO,negative
934168.0,"The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan",2019-02-21 07:32:00-05:00,NVRO,positive
934169.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,NVRO,neutral
934170.0,Nevro Files Lawsuit For Patent Infringement Against Stimwave In The US,2019-02-15 08:05:00-05:00,NVRO,negative
934171.0,25 Stocks Moving In Wednesday's Pre-Market Session,2019-01-30 08:12:00-05:00,NVRO,neutral
934172.0,Nevro Sees FY2018 Sales $386.90M-387.40M vs $385.46M Est,2019-01-07 09:06:00-05:00,NVRO,neutral
934173.0,Nevro Sees Q4 Sales $107.60M-108.10M vs $106.15M Est,2019-01-07 09:05:00-05:00,NVRO,neutral
934174.0,"UBS Initiates Coverage On Nevro with Sell Rating, Announces $35 Price Target",2018-11-28 08:13:00-05:00,NVRO,neutral
934175.0,Bank Of America On Nevro: Cannot Recommend NVRO 'on the hope that strategic value is realized alone',2018-11-07 12:30:00-05:00,NVRO,positive
934176.0,Bank of America Downgrades Nevro to Neutral,2018-11-07 08:07:00-05:00,NVRO,neutral
934177.0,75 Biggest Movers From Yesterday,2018-11-07 04:00:00-05:00,NVRO,neutral
934178.0,"Morgan Stanley Downgrades Nevro to Underweight, Lowers Price Target to $43",2018-11-06 10:31:00-05:00,NVRO,negative
934179.0,7 Biggest Price Target Changes For Tuesday,2018-11-06 09:45:00-05:00,NVRO,neutral
934180.0,"Wells Fargo Maintains Market Perform on Nevro, Lowers Price Target to $50",2018-11-06 09:29:00-05:00,NVRO,positive
934181.0,"Benzinga's Top Upgrades, Downgrades For November 6, 2018",2018-11-06 09:01:00-05:00,NVRO,positive
934182.0,"JP Morgan Downgrades Nevro to Neutral, Lowers Price Target to $45",2018-11-06 07:43:00-05:00,NVRO,positive
934183.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,NVRO,positive
934184.0,Nevro Corp. Sees FY18 Sales At Lower End Of Guidance Range Of $385M-$390M vs $385.81M Est.,2018-11-05 16:11:00-05:00,NVRO,negative
934185.0,"Nevro Corp. Common Stock Q3 EPS $(0.37) Misses $(0.29) Estimate, Sales $95.63M Beat $94.28M Estimate",2018-11-05 16:11:00-05:00,NVRO,negative
934186.0,10 Biggest Price Target Changes For Friday,2018-10-19 09:55:00-04:00,NVRO,neutral
934187.0,"Benzinga's Top Upgrades, Downgrades For October 19, 2018",2018-10-19 09:17:00-04:00,NVRO,positive
934188.0,"Goldman Sachs Downgrades Nevro to Sell, Lowers Price Target to $44",2018-10-19 06:27:00-04:00,NVRO,negative
934189.0,40 Stocks Moving In Thursday's Pre-Market Session,2018-08-09 08:09:00-04:00,NVRO,neutral
934190.0,Nevro Sees FY18 Sales $385M-$390M vs $386.88M Est.,2018-08-02 16:36:00-04:00,NVRO,neutral
934191.0,"Nevro Corp. Common Stock Q2 EPS $(0.35) Misses $(0.31) Estimate, Sales $96.08M Beat $95.31M Estimate",2018-08-02 16:36:00-04:00,NVRO,negative
934192.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,NVRO,positive
934193.0,"Nevro Reports Co., Boston Scientific Have Filed To Dismiss Remaining Claims; Boston Scientific Represents It Has No Plans to Launch High Frequency Products",2018-07-30 08:34:00-04:00,NVRO,negative
934194.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,NVRO,neutral
934195.0,50 Biggest Movers From Yesterday,2018-07-26 04:16:00-04:00,NVRO,neutral
934196.0,Buying The Dip In Nevro Pays Off For Investors After Court Ruling,2018-07-25 15:22:00-04:00,NVRO,neutral
934197.0,Mid-Afternoon Market Update: U.S. Stocks Turn Higher; Travelzoo Shares Slide,2018-07-25 14:56:00-04:00,NVRO,positive
934198.0,36 Stocks Moving In Wednesday's Mid-Day Session,2018-07-25 12:50:00-04:00,NVRO,neutral
934199.0,Mid-Day Market Update: Crude Oil Up Over 1%; Agile Therapeutics Shares Plunge,2018-07-25 12:21:00-04:00,NVRO,negative
934200.0,"Stocks Which Set New 52-Week Lows Yesterday, July 24th:",2018-07-25 12:17:00-04:00,NVRO,negative
934201.0,Mid-Morning Market Update: Markets Mostly Lower; Coca-Cola Tops Q2 Views,2018-07-25 10:14:00-04:00,NVRO,positive
934202.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-25 09:20:00-04:00,NVRO,neutral
934203.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,NVRO,positive
934204.0,22 Stocks Moving In Wednesday's Pre-Market Session,2018-07-25 08:01:00-04:00,NVRO,neutral
934205.0,46 Biggest Movers From Yesterday,2018-07-25 04:03:00-04:00,NVRO,neutral
934206.0,Nevro Announces Patent Litigation Update; Says Court Found that Boston Scientific is Not Currently Infringing Six Upheld Method Claims,2018-07-25 03:48:00-04:00,NVRO,negative
934207.0,7 Stocks Moving In Tuesday's After-Hours Session,2018-07-24 16:54:00-04:00,NVRO,neutral
934208.0,"UPDATE: US District Court Doc Related To Boston Scientific, Nevro Shows 'Motions To Strike Filed By Both Parties Are Denied As Moot'",2018-07-24 15:49:00-04:00,NVRO,negative
934209.0,Nevro Shares Now Down 28%; Traders Circulating Doc From US District Judge Showing Conference Scheduled For Aug. 2 To Confirm 'No Live Claims Remain...Judgment Can Be Entered In Full For Boston Scientific',2018-07-24 15:47:00-04:00,NVRO,neutral
934210.0,Downside In Nevro Shares Intensifies As $50 Support Level Breaks; Stock Now Down ~37.4% To Below $40,2018-07-24 15:42:00-04:00,NVRO,positive
934211.0,UPDATE: Nevro Shares Fall Below $60 For First Time Since Early 2016; Not Seeing News To Justify Mid-Day Dip Below That Support Level,2018-07-24 15:18:00-04:00,NVRO,positive
934212.0,"Nevro Shares Fall Below $60 Level, Down ~9% Over Last Min.",2018-07-24 15:15:00-04:00,NVRO,positive
934213.0,"Leerink Swann Maintains Outperform on Nevro, Lowers Price Target to $90",2018-07-19 08:17:00-04:00,NVRO,negative
934214.0,"Wells Fargo Maintains Market Perform on Nevro, Lowers Price Target to $62",2018-07-17 11:08:00-04:00,NVRO,positive
934215.0,"Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $65",2018-07-17 07:49:00-04:00,NVRO,negative
934216.0,Hearing Leerink Cut Nevro Corp Price Target From $95 To $90,2018-07-16 17:45:00-04:00,NVRO,negative
934217.0,"Canaccord Genuity Maintains Buy on Nevro, Lowers Price Target to $83",2018-07-16 08:10:00-04:00,NVRO,negative
934218.0,Nevro Raises FY2018 Sales Guidance from $385.0M-390.0M to $400.0M-410.0M vs $403.13M Est,2018-07-16 08:07:00-04:00,NVRO,neutral
934219.0,Nevro Sees Q2 Sales $96.10M vs $95.44M Est,2018-07-16 08:06:00-04:00,NVRO,neutral
934220.0,38 Biggest Movers From Friday,2018-07-16 04:47:00-04:00,NVRO,neutral
934221.0,30 Stocks Moving In Friday's Mid-Day Session,2018-07-13 12:38:00-04:00,NVRO,neutral
934222.0,Nevro Shares Down 14.3% Following An 8-K From The Co. Earlier Today Announcing The Decision To Terminate James Alecxih's Employment As VP Of Worldwide Sales,2018-07-13 10:06:00-04:00,NVRO,positive
934223.0,"Nevro Shares Close Up 4.9% After Receiving Positive Mention From Canaccord Genuity, Which Noted A Favorable Risk Reward Setup In The Shares After Tuesday's Sell-Off",2018-07-11 16:29:00-04:00,NVRO,positive
934224.0,41 Biggest Movers From Yesterday,2018-07-11 04:38:00-04:00,NVRO,neutral
934225.0,Nevro Shares Down 16.2%; Price Action May Or May Not Be Related To Traders Passing Media Report Out Yesterday Highlighting Action Last Week In The Co.'s Patent Suit With Boston Scientific,2018-07-10 14:56:00-04:00,NVRO,positive
934226.0,44 Biggest Movers From Yesterday,2018-07-03 05:54:00-04:00,NVRO,neutral
934227.0,38 Stocks Moving In Monday's Mid-Day Session,2018-07-02 12:29:00-04:00,NVRO,neutral
934228.0,3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley,2018-07-02 12:01:00-04:00,NVRO,neutral
934229.0,"Benzinga's Top Upgrades, Downgrades For July 2, 2018",2018-07-02 09:21:00-04:00,NVRO,positive
934230.0,Morgan Stanley Downgrades Nevro to Equal-Weight,2018-07-02 06:38:00-04:00,NVRO,neutral
934231.0,53 Biggest Movers From Yesterday,2018-05-09 05:37:00-04:00,NVRO,neutral
934232.0,36 Stocks Moving In Tuesday's Mid-Day Session,2018-05-08 14:26:00-04:00,NVRO,neutral
934233.0,Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report,2018-05-08 14:24:00-04:00,NVRO,negative
934234.0,Mid-Morning Market Update: Markets Edge Lower; DISH Network Revenue Misses Expectations,2018-05-08 09:48:00-04:00,NVRO,negative
934235.0,"Canaccord Genuity Maintains Buy on Nevro, Lowers Price Target to $102",2018-05-08 09:41:00-04:00,NVRO,negative
934236.0,"Benzinga's Top Upgrades, Downgrades For May 8, 2018",2018-05-08 09:19:00-04:00,NVRO,positive
934237.0,Northland Securities Downgrades Nevro to Market Perform,2018-05-08 08:43:00-04:00,NVRO,positive
934238.0,"JMP Securities Maintains Market Outperform on Nevro, Lowers Price Target to $105",2018-05-08 08:07:00-04:00,NVRO,positive
934239.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-05-08 08:03:00-04:00,NVRO,neutral
934240.0,Wells Fargo Downgrades Nevro to Market Perform,2018-05-08 07:42:00-04:00,NVRO,positive
934241.0,Nevro Corp Shares Down 15.8% After Hours Following Q1 Miss,2018-05-07 18:04:00-04:00,NVRO,positive
934242.0,9 Stocks Moving In Monday's After-Hours Session,2018-05-07 17:06:00-04:00,NVRO,neutral
934243.0,Nevro Reaffirms FY2018 Sales Guidance $400.0M-410.0M vs $406.0M Est,2018-05-07 17:03:00-04:00,NVRO,neutral
934244.0,"Nevro Corp. Common Stock Q1 EPS $(0.59) Misses $(0.30) Estimate, Sales $87.635M Miss $89.47M Estimate",2018-05-07 17:02:00-04:00,NVRO,negative
934245.0,"Goldman Sachs Initiates Coverage On Nevro with Neutral Rating, Announces $83.00 Price Target",2018-04-04 08:36:00-04:00,NVRO,neutral
934246.0,"Nevro Reports Q4 EPS $(0.15) vs. $(0.14) Est., Sales $97.96M vs. $95.34M Est.",2018-02-22 16:13:00-05:00,NVRO,neutral
934247.0,48 Biggest Movers From Yesterday,2018-01-09 06:07:00-05:00,NVRO,neutral
934248.0,Mid-Afternoon Market Update: NASDAQ Gains 0.2%; GoPro Shares Spike Higher,2018-01-08 14:31:00-05:00,NVRO,positive
934249.0,Nevro Shares Up 16.26%; Ealrier Co. Reported Receipt Of FDA Approval For Senza II System,2018-01-08 12:26:00-05:00,NVRO,positive
934250.0,38 Stocks Moving In Monday's Mid-Day Session,2018-01-08 12:20:00-05:00,NVRO,neutral
934251.0,Mid-Day Market Update: Dave & Buster's Drops On Lowered Outlook; Nevro Shares Surge,2018-01-08 12:03:00-05:00,NVRO,positive
934252.0,Nevro Sees Q4 Sales $97.4M-$97.9M vs $90.4M Est.; Sees FY17 Sales $326.1M-$326.6M vs $319M Est.,2018-01-08 07:35:00-05:00,NVRO,neutral
934253.0,Nevro Narrows FY17 Sales From $310-$320M To $315-$320M,2017-11-06 16:28:00-05:00,NVRO,neutral
934254.0,"Nevro Reports Q3 EPS $(0.21) vs $(0.22) Est., Sales $82.2M vs $80.4M Est.",2017-11-06 16:27:00-05:00,NVRO,neutral
934255.0,Nevro Sees FY17 Sales $310M-$320M vs $316.95M Est.,2017-08-07 16:51:00-04:00,NVRO,neutral
934256.0,"Nevro Reports Q2 EPS $(0.40) vs $(0.30) Est., Sales $78.016M vs $74.96M Est.",2017-08-07 16:50:00-04:00,NVRO,neutral
934257.0,12 Biggest Mid-Day Gainers For Wednesday,2017-07-05 13:05:00-04:00,NVRO,neutral
934258.0,Mid-Day Market Update: NASDAQ Turns Positive; O'Reilly Shares Drop Following Disappointing Comparable Store Sales,2017-07-05 12:29:00-04:00,NVRO,positive
934259.0,Nevro Corp Shares Moving 10% Higher After Reporting A Strong Q2 Sales Forecast,2017-07-05 11:53:00-04:00,NVRO,positive
934260.0,Mid-Morning Market Update: Markets Drop; Vantiv To Acquire Worldpay,2017-07-05 10:19:00-04:00,NVRO,negative
934261.0,Nevro Sees FY Sales $310M to $320M vs $316M Est,2017-07-05 07:00:00-04:00,NVRO,neutral
934262.0,Nevro Sees Q2 Sales $77.5M to $78.0M vs $74.1M Est,2017-07-05 06:59:00-04:00,NVRO,neutral
934263.0,20 Biggest Mid-Day Losers For Tuesday,2017-05-09 12:32:00-04:00,NVRO,negative
934264.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-05-09 08:16:00-04:00,NVRO,neutral
934265.0,B. Riley Downgrades Nevro to Neutral,2017-05-09 06:34:00-04:00,NVRO,neutral
934266.0,"Nevro Reports Q1 EPS $(0.50) May Not Compare To $(0.25) Est., Sales $68.439M vs $68.71M Est.",2017-05-08 17:23:00-04:00,NVRO,neutral
934267.0,"Nevro Reports Q4 EPS $(0.34) vs $(0.20) Est., Sales $70.5M vs $66.41M Est.",2017-02-23 16:11:00-05:00,NVRO,neutral
934268.0,Boston Scientific Files Patent Lawsuit Against Nevro,2016-12-09 17:24:00-05:00,NVRO,negative
934269.0,8-K from Nevro Shows Co. Entered Multi-Year Supply Deal with Centro de Construccion de Cardioestimuladores del uruguay,2016-11-21 17:05:00-05:00,NVRO,neutral
934270.0,18 Biggest Mid-Day Losers For Tuesday,2016-11-08 14:08:00-05:00,NVRO,negative
934271.0,22 Stocks Moving In Tuesday's Pre-Market Session,2016-11-08 08:34:00-05:00,NVRO,neutral
934272.0,UPDATE: Nevro Raises FY16 Revenue Guidance From $210M-$220M To $220M-$225M vs $222.22M Est,2016-11-07 16:13:00-05:00,NVRO,neutral
934273.0,"Nevro Reports Q3 Loss/Share $0.14 vs Est Loss/Share $0.40, Rev $60.9M vs $58.05M Est",2016-11-07 16:12:00-05:00,NVRO,neutral
934274.0,Nevro Raises FY16 Revenue Guidance,2016-11-07 16:11:00-05:00,NVRO,neutral
934275.0,Nevro Spikes to High of $104.14 on Volume,2016-09-26 11:36:00-04:00,NVRO,neutral
934276.0,"B. Riley Initiates Coverage on Nevro at Buy, Announces $114.00 PT",2016-09-16 06:09:00-04:00,NVRO,neutral
934277.0,Nevro Corp. Reports SENZA-RCT Results Show Sustained Superiority Of HF10 Over Traditional Spinal Cord Stimulation For Chronic Pain Across All Primary & Secondary Endpoints,2016-09-06 07:34:00-04:00,NVRO,negative
934278.0,18 Biggest Mid-Day Gainers For Tuesday,2016-08-09 12:44:00-04:00,NVRO,neutral
934279.0,Benzinga's Volume Movers,2016-08-09 10:46:00-04:00,NVRO,neutral
934280.0,22 Stocks Moving In Tuesday's Pre-Market Session,2016-08-09 08:48:00-04:00,NVRO,neutral
934281.0,"After-Hours Gainers Aug. 8, 2016: HIIQ Up 36%, REN 20%, CCXI 14.4%, FH 14.3%, FGEN 10.4%, AMPH 9.4%, CSLT 8.9%, NVRO 8.7%, ENDP 7.5%",2016-08-08 18:58:00-04:00,NVRO,neutral
934282.0,Nevro updates FY 16 guidance,2016-08-08 16:13:00-04:00,NVRO,neutral
934283.0,"Nevro Reports Q2 Loss/Share ($0.31) vs Est Loss/Share ($0.47), Rev $55.4M vs $45.11M Est",2016-08-08 16:12:00-04:00,NVRO,neutral
934284.0,Nevro Initiated With Buy Rating At Bank Of America,2016-08-08 16:04:00-04:00,NVRO,neutral
934285.0,Benzinga's Top Initiations,2016-08-08 09:40:00-04:00,NVRO,positive
934286.0,Bank of America Initiates Coverage on Nevro at Buy,2016-08-08 08:12:00-04:00,NVRO,neutral
934287.0,Benzinga's Top Initiations,2016-07-22 09:31:00-04:00,NVRO,positive
934288.0,The Market In 5 Minutes: The Dow's Win Streak Comes To An End,2016-07-22 08:55:00-04:00,NVRO,positive
934289.0,PiperJaffray Initiates Coverage on Nevro at Overweight,2016-07-22 07:15:00-04:00,NVRO,negative
934290.0,William Blair Initiates Coverage on Nevro at Outperform,2016-07-19 08:33:00-04:00,NVRO,neutral
934291.0,Wells Fargo Initiates Coverage on Nevro at Outperform,2016-07-12 06:26:00-04:00,NVRO,positive
934292.0,Option Alert: NVRO Jun16 75.0 Puts: 1800 @  ASK  $4.20: 1800 traded vs 1861 OI:  Earnings 8/4  $71.94 Ref,2016-06-14 11:18:00-04:00,NVRO,positive
934293.0,Nevro Prices Public Offering of $150M of 1.75% Convertible Senior Notes,2016-06-08 04:04:00-04:00,NVRO,neutral
934294.0,"Nevro Raises FY 2016 Revenue Guidance, Sees Revenue $175M to $185M vs $165.97M est",2016-05-09 16:19:00-04:00,NVRO,neutral
934295.0,"Nervo Q1 EPS ($0.33) vs ($0.63) est, Revenue $41.65M vs $33.48M est",2016-05-09 16:18:00-04:00,NVRO,neutral
934296.0,Nevro Has A Multi-Billion Dollar Opportunity,2016-04-26 11:50:00-04:00,NVRO,positive
934297.0,Nevro Reports FDA Approval of New Surgical Leads for Senza Spinal Cord Stimulation System Delivering HF10 Therapy,2016-04-15 14:01:00-04:00,NVRO,positive
934298.0,"Northland Securities Initiates Coverage on Nevro at Market Perform, Announces $48.00 PT",2016-03-29 08:54:00-04:00,NVRO,positive
934299.0,"Nevro Announce CEO to Become Chairman of Board, Rami Elghandour to Become CEO",2016-02-29 16:14:00-05:00,NVRO,neutral
934300.0,"Nervo Raises FY 2016 Sales $155M-$165M Vs Est $149.77M, Had Seen $145M-$155M",2016-02-29 16:11:00-05:00,NVRO,neutral
934301.0,"Nervo Reports Q4 EPS $(0.51) Vs Est $(0.56), Sales $33.1M Vs Est $32.88M, CEO To Transition To Role Of Exec. Chairman",2016-02-29 16:10:00-05:00,NVRO,neutral
934302.0,Nevro Sells Off to Low of $55 on Volume,2016-02-05 15:45:00-05:00,NVRO,negative
934303.0,Stocks Hitting 52-Week Highs,2016-01-11 10:19:00-05:00,NVRO,neutral
934304.0,Nevro Sees FY2016 Sales $145.0M-155.0M vs $134.40M Est,2016-01-11 07:32:00-05:00,NVRO,neutral
934305.0,Nevro Sees Q4 Sales $32.60M-33.10M vs $24.01M Est,2016-01-11 07:31:00-05:00,NVRO,neutral
934306.0,Option Alert: NVRO Jan16 70.0 Calls Sweep: 1001 @  ASK  $1.54: 1001 traded vs 94 OI: $65.73 Ref,2016-01-04 11:51:00-05:00,NVRO,positive
934307.0,"J.P. Morgan Thinks Nervo Is About To Take Off, Sees Major Revenues Coming",2015-12-14 10:25:00-05:00,NVRO,neutral
934308.0,Stocks Hitting 52-Week Highs,2015-12-14 10:05:00-05:00,NVRO,neutral
934309.0,Nevro Announces CMS Approved Transitional Pass-through Payment for Outpatient Use of Co.'s Senza Spinal Cord Stimulation System,2015-12-10 07:35:00-05:00,NVRO,positive
934310.0,"Nevro Announces USPTO Denies Boston Scientific Petitions for Inter Partes Review of U.S. Patent No. 8,359,102",2015-12-01 04:15:00-05:00,NVRO,negative
934311.0,"Nevro Spikes to High of $60,19",2015-11-30 15:38:00-05:00,NVRO,neutral
934312.0,"Shares of Nevro Jump $0.70 Over Last Two Mins, Now Up ~0.5% for the Session",2015-11-30 15:26:00-05:00,NVRO,positive
934313.0,Benzinga's Volume Movers,2015-11-10 10:49:00-05:00,NVRO,neutral
934314.0,Nevro Sees FY15 Sales $59.5M-$61.5M vs $50.6M Est.,2015-11-09 16:43:00-05:00,NVRO,neutral
934315.0,"Nevro Reports Q3 EPS $(0.70) vs $(0.75) Est., Sales $15.402M vs $12.5M Est.",2015-11-09 16:42:00-05:00,NVRO,neutral
934316.0,Benzinga's Top Initiations,2015-09-25 09:29:00-04:00,NVRO,positive
934317.0,"BMO Capital Initiates Coverage on Nevro at Outperform, Announces $65.00 PT",2015-09-25 06:09:00-04:00,NVRO,neutral
934318.0,Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board,2015-09-01 16:14:00-04:00,NVRO,neutral
934319.0,"Nevro Reports Q2 EPS $(0.77) vs. Est. $(0.89), Rev. $11.418M vs. Est. $9.7M",2015-08-06 18:13:00-04:00,NVRO,neutral
934320.0,Benzinga's Volume Movers,2015-06-18 10:21:00-04:00,NVRO,neutral
934321.0,Nevro Prices Upsized ~4.705M Offering @$51.00/Share,2015-06-03 04:34:00-04:00,NVRO,neutral
934322.0,"Nevro Announces Offering of ~1.476M Common Shares by Co., ~2.459M Shares by Selling Holders",2015-06-01 16:02:00-04:00,NVRO,positive
934323.0,"S-1 from Nevro Corp. Shows Registration for $200M Offering, $75M via Co., $125M via Selling Holders",2015-05-18 16:21:00-04:00,NVRO,neutral
934324.0,Leerink Is Changing Targets At These 7 Biotechs,2015-05-12 12:54:00-04:00,NVRO,neutral
934325.0,"Nevro Announces Boston Scientific Unit Files Petitions for Inter Partes Review of U.S. Patent No. 8,359,102",2015-05-12 04:55:00-04:00,NVRO,negative
934326.0,Mid-Day Market Update: U.S. Stocks Mostly Lower; Rosetta Resources Shares Rise On Acquisition News,2015-05-11 13:13:00-04:00,NVRO,neutral
934327.0,Benzinga's Volume Movers,2015-05-11 10:22:00-04:00,NVRO,neutral
934328.0,Mid-Morning Market Update: Markets Edge Higher; Dean Foods Earnings Beat Views,2015-05-11 10:14:00-04:00,NVRO,neutral
934329.0,Stocks Hitting 52-Week Highs,2015-05-11 10:13:00-04:00,NVRO,neutral
934330.0,Morning Market Gainers,2015-05-11 09:48:00-04:00,NVRO,neutral
934331.0,"Nevro Reports Q1 EPS $(0.57) vs. Est. $(0.63), Rev. 9.662M vs. Est. $8.53M",2015-05-11 07:37:00-04:00,NVRO,neutral
934332.0,Nevro Receives FDA Approval for Senza Spinal Cord Stimulation System,2015-05-09 05:33:00-04:00,NVRO,positive
934333.0,Stocks Hitting 52-Week Highs,2015-03-19 10:26:00-04:00,NVRO,neutral
934334.0,Morning Market Gainers,2015-03-19 10:02:00-04:00,NVRO,neutral
934335.0,"Nevro Reports Q4 EPS $(0.59) vs. Est. $(0.54), Rev. $9.7M vs. Est. $8.4M",2015-03-18 16:03:00-04:00,NVRO,neutral
934336.0,CRT Capital Initiates Coverage on Nevro at Buy,2015-03-10 07:15:00-04:00,NVRO,neutral
934337.0,"CRT Capital Initiates Coverage on Nevro at Buy, Announces $55.00 PT",2015-03-09 16:56:00-04:00,NVRO,neutral
934338.0,Why Nevro Is Trading 25% Higher,2015-01-23 12:18:00-05:00,NVRO,neutral
934339.0,Stocks Hitting 52-Week Highs,2015-01-23 10:22:00-05:00,NVRO,neutral
934340.0,Morning Market Gainers,2015-01-23 09:53:00-05:00,NVRO,neutral
934341.0,Nevro Receives Approvable Letter from FDA for Senza Spinal Cord Stimulation System,2015-01-22 19:31:00-05:00,NVRO,neutral
934342.0,UPDATE: Morgan Stanley Reiterates On Nevro On Improving Margins,2014-12-03 10:04:00-05:00,NVRO,positive
934343.0,"Shares of Nevro Open for Trade at $23.40/Share, IPO Priced at $18",2014-11-06 09:41:00-05:00,NVRO,positive
934344.0,Expected IPOs For November 6,2014-11-06 09:23:00-05:00,NVRO,neutral
934345.0,Nevro Prices 7M Share IPO @$18.00/Share,2014-11-06 05:10:00-05:00,NVRO,positive
934346.0,Nevro Corp. Expects 6.25M Share IPO to Price $15.00-$17.00/Share,2014-10-27 06:25:00-04:00,NVRO,positive
